FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2503670448> ?p ?o ?g. }

• W2503670448 endingPage "1762" @default.
• W2503670448 startingPage "1753" @default.
• W2503670448 abstract "Treatments for Crohn's disease (CD) have been linked to serious infections, malignancies, and dermatologic complications. We pooled and analyzed clinical trials of certolizumab pegol, a pegylated humanized Fab' fragment against tumor necrosis factor, to quantify safety events in patients with CD.We collected data from 5 placebo-controlled trials, 9 open-label studies, and 1 dose-regimen study, conducted globally through April 2014. A total of 2570 patients with moderate to severe CD were treated with certolizumab pegol, with 4378.1 patient-years of exposure. Data were analyzed in 2 groups: patients from placebo-controlled (PC) trials treated with placebo (n = 875) or certolizumab pegol (n = 919) for 6 to 38 weeks (the PC group) or all patients exposed to certolizumab pegol (n = 2570), for durations of 6 to 362 weeks (the all-studies group). Incidence rates (IRs; incidence/100 patient-years) of adverse events (AEs) were calculated from first dose through 70 days (approximately 5 half-lives) after the last dose.In the PC group, IRs for serious AEs were similar among patients given certolizumab pegol (31.35/100 patient-years) vs placebo (24.33/100 patient-years). IRs of serious infections or malignancies were low among patients receiving short-term treatment with certolizumab pegol (8.49/100 patient-years and 1.01/100 patient-years, respectively, in the PC group) and did not increase with long-term treatment (6.47/100 patient-years and 0.80/100 patient-years, respectively, in the all-studies group). IRs of psoriasis or psoriasiform dermatitis were low in the PC group (1.01/100 patient-years and 0/100 patient-years, respectively); in the placebo group, these IRs were 0.38 per 100 patient-years and 0 per 100 patient-years, respectively. IRs of psoriasis or psoriasiform dermatitis did not increase with long-term treatment (0.93/100 patient-years and 0.09/100 patient-years, respectively, in the all-studies group).Based on an analysis of data pooled from 15 trials of patients with CD, the safety profile for long-term therapy with certolizumab pegol therapy is similar to that reported from short-term studies. Overall rates of AEs, serious infections, malignancies, and psoriasis did not increase with long-term treatment, suggesting a favorable risk-benefit ratio with long-term certolizumab pegol therapy in CD. Clinicaltrials.gov identifiers: NCT00291668, NCT00152490, NCT00152425, NCT00308581, NCT00349752, NCT00552058, NCT00329550, NCT00329420, NCT00160524, NCT00160706, NCT00297648, NCT00333788, NCT00307931, NCT00356408, and NCT00552344 (https://www.clinicaltrials.gov/ct2/search)." @default.
• W2503670448 created "2016-08-23" @default.
• W2503670448 creator A5002303350 @default.
• W2503670448 creator A5024421831 @default.
• W2503670448 creator A5027592480 @default.
• W2503670448 creator A5034722460 @default.
• W2503670448 creator A5037183472 @default.
• W2503670448 creator A5039252936 @default.
• W2503670448 creator A5039583547 @default.
• W2503670448 creator A5046814722 @default.
• W2503670448 creator A5049592171 @default.
• W2503670448 creator A5059435501 @default.
• W2503670448 date "2016-12-01" @default.
• W2503670448 modified "2023-10-14" @default.
• W2503670448 title "Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials" @default.
• W2503670448 cites W1891595854 @default.
• W2503670448 cites W1988105075 @default.
• W2503670448 cites W1989167852 @default.
• W2503670448 cites W1994625994 @default.
• W2503670448 cites W2002647452 @default.
• W2503670448 cites W2003777338 @default.
• W2503670448 cites W2018933969 @default.
• W2503670448 cites W2022301990 @default.
• W2503670448 cites W2044111577 @default.
• W2503670448 cites W2046549669 @default.
• W2503670448 cites W2049836762 @default.
• W2503670448 cites W2052675212 @default.
• W2503670448 cites W2056348171 @default.
• W2503670448 cites W2058050795 @default.
• W2503670448 cites W2071030284 @default.
• W2503670448 cites W2074007950 @default.
• W2503670448 cites W2080450248 @default.
• W2503670448 cites W2081436811 @default.
• W2503670448 cites W2100942700 @default.
• W2503670448 cites W2105532585 @default.
• W2503670448 cites W2112639375 @default.
• W2503670448 cites W2118810395 @default.
• W2503670448 cites W2123571431 @default.
• W2503670448 cites W2127632431 @default.
• W2503670448 cites W2133633410 @default.
• W2503670448 cites W2133741523 @default.
• W2503670448 cites W2135636312 @default.
• W2503670448 cites W2148189437 @default.
• W2503670448 cites W2156818981 @default.
• W2503670448 cites W2166360124 @default.
• W2503670448 cites W2168370388 @default.
• W2503670448 cites W2171341132 @default.
• W2503670448 cites W2317426648 @default.
• W2503670448 cites W2921874332 @default.
• W2503670448 doi "https://doi.org/10.1016/j.cgh.2016.07.019" @default.
• W2503670448 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27464588" @default.
• W2503670448 hasPublicationYear "2016" @default.
• W2503670448 type Work @default.
• W2503670448 sameAs 2503670448 @default.
• W2503670448 citedByCount "15" @default.
• W2503670448 countsByYear W25036704482018 @default.
• W2503670448 countsByYear W25036704482019 @default.
• W2503670448 countsByYear W25036704482020 @default.
• W2503670448 countsByYear W25036704482022 @default.
• W2503670448 crossrefType "journal-article" @default.
• W2503670448 hasAuthorship W2503670448A5002303350 @default.
• W2503670448 hasAuthorship W2503670448A5024421831 @default.
• W2503670448 hasAuthorship W2503670448A5027592480 @default.
• W2503670448 hasAuthorship W2503670448A5034722460 @default.
• W2503670448 hasAuthorship W2503670448A5037183472 @default.
• W2503670448 hasAuthorship W2503670448A5039252936 @default.
• W2503670448 hasAuthorship W2503670448A5039583547 @default.
• W2503670448 hasAuthorship W2503670448A5046814722 @default.
• W2503670448 hasAuthorship W2503670448A5049592171 @default.
• W2503670448 hasAuthorship W2503670448A5059435501 @default.
• W2503670448 hasBestOaLocation W25036704481 @default.
• W2503670448 hasConcept C120665830 @default.
• W2503670448 hasConcept C121332964 @default.
• W2503670448 hasConcept C126322002 @default.
• W2503670448 hasConcept C141071460 @default.
• W2503670448 hasConcept C142724271 @default.
• W2503670448 hasConcept C16005928 @default.
• W2503670448 hasConcept C197934379 @default.
• W2503670448 hasConcept C204787440 @default.
• W2503670448 hasConcept C27081682 @default.
• W2503670448 hasConcept C2776215756 @default.
• W2503670448 hasConcept C2777138892 @default.
• W2503670448 hasConcept C2779134260 @default.
• W2503670448 hasConcept C2780564577 @default.
• W2503670448 hasConcept C2781413609 @default.
• W2503670448 hasConcept C535046627 @default.
• W2503670448 hasConcept C61511704 @default.
• W2503670448 hasConcept C71924100 @default.
• W2503670448 hasConcept C90924648 @default.
• W2503670448 hasConceptScore W2503670448C120665830 @default.
• W2503670448 hasConceptScore W2503670448C121332964 @default.
• W2503670448 hasConceptScore W2503670448C126322002 @default.
• W2503670448 hasConceptScore W2503670448C141071460 @default.
• W2503670448 hasConceptScore W2503670448C142724271 @default.
• W2503670448 hasConceptScore W2503670448C16005928 @default.
• W2503670448 hasConceptScore W2503670448C197934379 @default.
• W2503670448 hasConceptScore W2503670448C204787440 @default.
• W2503670448 hasConceptScore W2503670448C27081682 @default.

• next